New recombinant vaccines for the prevention of meningococcal B disease

References

• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004;53(Pt 9):821–832.
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344(18):1378–1388.
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N; for National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1–21.
   PubMedGoogle Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. June 24, 2009;27 Suppl 2:B51-B63.
   Google Scholar
• National Advisory Committee on Immunization (NACI). An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2009;35(ACS-3):1–40.
   Google Scholar
• Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286(6):694–699.
   PubMed Web of Science ®Google Scholar
• Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19(1):142–164.
   PubMed Web of Science ®Google Scholar
• Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics. 2009;123(3):e502-e509.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Surveillance of Invasive Bacterial Diseases in Europe 2008/2009. Stockholm, Sweden: ECDC; 2011.
   Google Scholar
• Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50 Suppl 2:S37-S44.
   Google Scholar
• Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Travel Med. 2010;17 Suppl:3–8.
   Web of Science ®Google Scholar
• Dull P, Rosenstein N. Meningococcal disease and vaccines. Pediatr Ann. 2001;30(6):358–361.
   Web of Science ®Google Scholar
• Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31(1):3–14.
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992–1996. J Infect Dis. 1999;180(6):1894–1901.
   PubMed Web of Science ®Google Scholar
• Cartwright K, Noah N, Peltola H; for Meningococcal Disease Advisory Boad. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, October 6–8, 2000. Vaccine. 2001;19(31):4347–4356.
   Google Scholar
• Bhattacharjee AK, Jennings HJ. Determination of the linkages in some methylated, sialic acid-containing, meningococcal polysaccharides by mass spectrometry. Carbohydr Res. 1976;51(2):253–261.
   Web of Science ®Google Scholar
• Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IC. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J Biol Chem. 1975;250(5):1926–1932.
   Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326.
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine. 2005;23(17–18):2222–2227.
   PubMed Web of Science ®Google Scholar
• van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13(1):144–166.
   PubMed Web of Science ®Google Scholar
• Grabenstein JD, Pittman PR, Greenwood JT, Engler RJ. Immunization to protect the US Armed Forces: heritage, current practice, and prospects. Epidemiol Rev. 2006;28:3–26.
   PubMed Web of Science ®Google Scholar
• Tyler KL. Chapter 28: a history of bacterial meningitis. Handb Clin Neurol. 2010;95:417–433.
   Google Scholar
• Brundage JF, Ryan MA, Feighner BH, Erdtmann FJ. Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964–1998. Clin Infect Dis. 2002;35(11):1376–1381.
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969;129(6):1367–1384.
   PubMed Web of Science ®Google Scholar
• Ada G. Vaccines and vaccination. N Engl J Med. 2001;345(14):1042–1053.
   PubMed Web of Science ®Google Scholar
• Goldblatt D. Recent developments in bacterial conjugate vaccines. J Med Microbiol. 1998;47(7):563–567.
   PubMed Web of Science ®Google Scholar
• Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines. 2011;10(3):307–322.
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–1520.
   PubMed Web of Science ®Google Scholar
• Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126(5):514–521.
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987;138(12):4402–4407.
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Mühlenhoff M, Bethe A, Koopman J, Frosch M, Gerardy-Schahn R. Molecular characterization of eukaryotic polysialyltransferase-1. Nature. 1995;373(6516):715–718.
   Web of Science ®Google Scholar
• Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27 Suppl 2:B3-B12.
   Google Scholar
• Holst J, Feiring B, Naess LM, et al. The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine. 2005;23(17–18):2202–2205.
   PubMed Web of Science ®Google Scholar
• Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50 Suppl 2:S54-S65.
   Google Scholar
• Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281(16):1520–1527.
   PubMed Web of Science ®Google Scholar
• Poolman JT. Development of a meningococcal vaccine. Infect Agents Dis. 1995;4(1):13–28.
   PubMedGoogle Scholar
• Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol. 2000;38(9):3323–3328.
   PubMed Web of Science ®Google Scholar
• Oster P, O’Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine. 2007;25(16):3075–3079.
   Web of Science ®Google Scholar
• Caron F, du Chatelet IP, Leroy JP, et al. From tailor-made to ready- to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455–463.
   PubMed Web of Science ®Google Scholar
• Nokleby H, Aavitsland P, O’Hallahan J, Feiring B, Tilman S, Oster P Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 2007;25(16):3080–3084.
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Labadie J, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine. 2000;18(15):1456–1466.
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Lafeber AB, et al. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine. 2000;19(9–10):1141–1148.
   PubMed Web of Science ®Google Scholar
• Cartwright K, Morris R, Rumke H, et al. Immunogenicity and reac- togenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine. 1999;17(20–21):2612–2619.
   PubMed Web of Science ®Google Scholar
• Bambini S, Rappuoli R. The use of genomics in microbial vaccine development. Drug Discov Today. 2009;14(5–6):252–260.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19(17–19):2688–2691.
   PubMed Web of Science ®Google Scholar
• Su EL, Snape MD. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. Expert Rev Vaccines. 2011;10(5):575–588.
   PubMed Web of Science ®Google Scholar
• Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000;287(5459):1809–1815.
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. July 18, 2006;103(29):10834–10839.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7(6):646–653.
   PubMed Web of Science ®Google Scholar
• Toneatto D, Oster P, deBoer AC, et al. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin. 2011;7(7):781–791.
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21(7–8):734–737.
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71-e79.
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–1137.
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–582.
   PubMed Web of Science ®Google Scholar
• Prymula R, Siegrist CA, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339–1350.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–624.
   PubMed Web of Science ®Google Scholar
• Whittle HC, Abdullahi MT, Fakunle FA, et al. Allertic complications of meningococcal disease. I. Clinical aspects. Br Med J. 1973;2(5869):733–737.
   PubMedGoogle Scholar
• Cohn AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants. JAMA. 2012;307(6):614–615.
   Web of Science ®Google Scholar
• Brehony C, Wilson DJ, Maiden MC. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology. 2009;155(Pt 12):4155–4169.
   PubMedGoogle Scholar
• Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379–389.
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med. 2002;195(11):1445–1454.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490–19495.
   PubMed Web of Science ®Google Scholar
• Fletcher LD, Bernfield L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72(4):2088–2100.
   PubMed Web of Science ®Google Scholar
• Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, singleblind, placebo-controlled, phase 2 trial. Lancet Infect Dis. May 4, 2012. [Epub ahead of print.]
   Google Scholar
• Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28(37):6086–6093.
   PubMed Web of Science ®Google Scholar
• Taha MK, Deghmane AE. Vaccines targeting serogroup B meningococci. Lancet Infect Dis. May 4, 2012. [Epub ahead of print.]
   Web of Science ®Google Scholar
• Zollinger WD, Poolman JT, Maiden MC. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines. 2011;10(5):559–561.
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Pajon R. Bexsero: A multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother. 2012;8(2):174–183.
   PubMed Web of Science ®Google Scholar